| Psoriasis vulgaris

Enstilar vs Tremfya

Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.

Deep comparison between: Enstilar vs Tremfya with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTremfya has a higher rate of injection site reactions vs Enstilar based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tremfya but not Enstilar, including UnitedHealthcare

Category

Enstilar

Tremfya

At A Glance

RouteTopical

FrequencyOnce daily

ClassVitamin D3 analog + corticosteroid

RouteSubcutaneous / Intravenous

FrequencyEvery 4-8 weeks

ClassInterleukin-23 antagonist

Indications

Psoriasis vulgaris

Psoriasis vulgaris
Arthritis, Psoriatic
Ulcerative Colitis
Crohn Disease

Dosing

Psoriasis vulgaris Apply to affected areas once daily for up to 4 weeks; maximum dose not to exceed 60 g every 4 days; rub in gently; do not use with occlusive dressings, on the face, groin, or axillae, or if skin atrophy is present at the treatment site.

Psoriasis vulgaris Adults: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter. Pediatric patients >=6 years and >=40 kg: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter.

Arthritis, Psoriatic Adults: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter, alone or with conventional DMARD. Pediatric patients >=6 years and >=40 kg: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter, alone or with conventional DMARD.

Ulcerative Colitis Induction: 200 mg intravenous infusion over at least one hour at Week 0, 4, and 8, or 400 mg subcutaneous injection at Week 0, 4, and 8. Maintenance: 100 mg subcutaneous injection at Week 16 and every 8 weeks thereafter, or 200 mg subcutaneous injection at Week 12 and every 4 weeks thereafter.

Crohn Disease Induction: 200 mg intravenous infusion over at least one hour at Week 0, 4, and 8, or 400 mg subcutaneous injection at Week 0, 4, and 8. Maintenance: 100 mg subcutaneous injection at Week 16 and every 8 weeks thereafter, or 200 mg subcutaneous injection at Week 12 and every 4 weeks thereafter.

Contraindications

—

History of serious hypersensitivity reaction to guselkumab or to any of the excipients

Drug Interactions

841View drug interactions

378View drug interactions

Adverse Reactions

Postmarketing Application site burning, atrophy, striae, telangiectasia, dryness, perioral dermatitis, secondary infection, miliaria, cataracts, glaucoma, increased intraocular pressure.

Most common (>=1%) Upper respiratory infections (14.3%), headache (4.6%), injection site reactions (4.5%), arthralgia (2.7%), diarrhea (1.6%), gastroenteritis (1.3%), tinea infections (1.1%), herpes simplex infections (1.1%).

Serious Serious infections occurred in <=0.2% in plaque psoriasis trials through Week 16. In ulcerative colitis trials, serious infections occurred in 0.8% with TREMFYA vs. 0% with placebo (44-week trial) and 1.8% vs. 0.7% (24-week trial). In Crohn's disease, serious infections occurred in 1.5% with TREMFYA vs. 0% with placebo.

Postmarketing Hypersensitivity including anaphylaxis, rash.

Pharmacology

Enstilar Foam combines calcipotriene hydrate, a synthetic vitamin D3 analog, and betamethasone dipropionate, a synthetic corticosteroid; exact mechanisms of action in the treatment of plaque psoriasis are unknown.

Guselkumab is a human monoclonal IgG1 lambda antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23) and inhibits its interaction with the IL-23 receptor, thereby inhibiting the release of proinflammatory cytokines and chemokines.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Enstilar